Patent: 7,560,436
✉ Email this page to a colleague
Summary for Patent: 7,560,436
Title: | Methods of treating gastrointestinal inflammation |
Abstract: | The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn\'s Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual. |
Inventor(s): | Raz; Eyal (Del Mar, CA), Katakura; Kyoko (San Diego, CA), Lee; Jongdae (San Diego, CA), Rachmilewitz; Daniel (Tel Aviv, IL) |
Assignee: | The Regents of the University of California (Oakland, CA) |
Application Number: | 11/359,945 |
Patent Claims: | see list of patent claims |
Details for Patent 7,560,436
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2025-02-22 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | ⤷ Try a Trial | 2025-02-22 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |